Press release
Health & Nutrition
September 30, 2021

Evonik to market AvailOm® omega-3 powder in India

  • Highest-load omega-3 powder and formulation service available for Indian nutraceutical companies
  • Strong market demand for dietary supplements in India
  • Continuous global roll-out of AvailOm®, following recent registration in Brazil

Essen, Germany. Evonik’s high-load omega-3 powder platform AvailOm® is now available in India. Evonik has received clearance from the Indian food safety authority FSSAI to import and distribute AvailOm® in India. Earlier this year, Evonik obtained registration of AvailOm® in Brazil, accelerating the global roll-out of its omega-3 solution.

“We are excited to enter the Asian market with India as the first country in the region to accept our AvailOm® omega-3 solution for distribution,” said Gilles Razzauti, director of Advanced Food Ingredients at Evonik’s Health Care business.

India is one of the countries with the lowest omega-3 index globally. The Indian population has an average of 4 percent EPA and DHA omega-3 fatty acids in the cell membranes of red blood cells. An ideal omega-3 level, however, is 8 percent or more.[1]

“We’re determined to offer Indian consumers an ideal opportunity to increase omega-3 levels in a convenient way. We look forward to working with Indian manufacturers to bring highly bioavailable nutraceuticals to market,” Razzauti continues.

AvailOm® has a bioavailability more than five times higher than traditional omega-3 fish oil soft-gel capsules. The powders are directly compressible into tablets and allow nutraceutical companies a wide range of opportunities to develop differentiated combination products with other active ingredients such as botanicals, vitamins, proteins and minerals for enhanced performance and synergistic benefits.

Evonik’s Health Care business is renowned for providing system solutions to customers in the pharmaceutical and nutraceutical industries. A global leader in advanced drug delivery, Evonik Health Care operates a large formulation laboratory and technical service centre in Mumbai, India. In addition to the AvailOm® omega-3 solution, the company can provide formulation know-how and technical support to regional customers.

Omega-3 is a critical ingredient in formulations for dietary supplements tailored to healthy agers, pregnant women, and other consumer groups. AvailOm® is produced using Evonik’s proprietary process that combines free fatty acids with the essential amino acid L-lysine. The complex formed is easy to process into a wide range of final formulations with no fishy aftertaste.

All AvailOm® grades are produced from certified sustainable sources to protect marine ecosystems.

[1] Stark KD, Van Elswyk ME, Higgins MR, Weatherford CA, Salem N Jr.

Global survey of the omega-3 fatty acids, docosahexaenoic acid and

eicosapentaenoic acid in the blood stream of healthy adults. Prog Lipid

Res. 2016;63:132–52.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around three billion euros in 2020 with about 5,300 employees.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.